Cargando…

CAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment

Hepatocellular carcinoma (HCC) is a lethal malignancy with a lack of effective treatments particularly for the disease at an advanced stage. Even though immune checkpoint inhibitors (ICIs) have made great progress in the treatment of HCC, durable and ideal clinical benefits still cannot be achieved...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Rui, Li, Jiayin, Hony, Jing, Xiao, Zhiwei, wang, Jinghui, Yao, Man, Liang, Shufang, Lu, Lingeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061011/
https://www.ncbi.nlm.nih.gov/pubmed/37006233
http://dx.doi.org/10.3389/fimmu.2023.1052657
_version_ 1785017206787014656
author Han, Rui
Li, Jiayin
Hony, Jing
Xiao, Zhiwei
wang, Jinghui
Yao, Man
Liang, Shufang
Lu, Lingeng
author_facet Han, Rui
Li, Jiayin
Hony, Jing
Xiao, Zhiwei
wang, Jinghui
Yao, Man
Liang, Shufang
Lu, Lingeng
author_sort Han, Rui
collection PubMed
description Hepatocellular carcinoma (HCC) is a lethal malignancy with a lack of effective treatments particularly for the disease at an advanced stage. Even though immune checkpoint inhibitors (ICIs) have made great progress in the treatment of HCC, durable and ideal clinical benefits still cannot be achieved in plenty of patients with HCC. Therefore, novel and refined ICI-based combination therapies are still needed to enhance the therapeutic effect. The latest study has reported that the carbonic anhydrase XII inhibitor (CAXIIi), a novel type of anticancer drug, can modify the tumor immunosuppression microenvironment by affecting hypoxic/acidic metabolism and alter the functions of monocytes and macrophages by regulating the expression of C-C motif chemokine ligand 8 (CCL8). These observations shine a light on improving programmed cell death protein 1 (PD-1)/programmed cell death ligand-1 (PD-L1) immunotherapy in combination with CAXIIis. This mini-review aims to ignite enthusiasm to explore the potential application of CAXIIis in combination with immunotherapy for HCC.
format Online
Article
Text
id pubmed-10061011
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100610112023-03-31 CAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment Han, Rui Li, Jiayin Hony, Jing Xiao, Zhiwei wang, Jinghui Yao, Man Liang, Shufang Lu, Lingeng Front Immunol Immunology Hepatocellular carcinoma (HCC) is a lethal malignancy with a lack of effective treatments particularly for the disease at an advanced stage. Even though immune checkpoint inhibitors (ICIs) have made great progress in the treatment of HCC, durable and ideal clinical benefits still cannot be achieved in plenty of patients with HCC. Therefore, novel and refined ICI-based combination therapies are still needed to enhance the therapeutic effect. The latest study has reported that the carbonic anhydrase XII inhibitor (CAXIIi), a novel type of anticancer drug, can modify the tumor immunosuppression microenvironment by affecting hypoxic/acidic metabolism and alter the functions of monocytes and macrophages by regulating the expression of C-C motif chemokine ligand 8 (CCL8). These observations shine a light on improving programmed cell death protein 1 (PD-1)/programmed cell death ligand-1 (PD-L1) immunotherapy in combination with CAXIIis. This mini-review aims to ignite enthusiasm to explore the potential application of CAXIIis in combination with immunotherapy for HCC. Frontiers Media S.A. 2023-03-16 /pmc/articles/PMC10061011/ /pubmed/37006233 http://dx.doi.org/10.3389/fimmu.2023.1052657 Text en Copyright © 2023 Han, Li, Hony, Xiao, wang, Yao, Liang and Lu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Han, Rui
Li, Jiayin
Hony, Jing
Xiao, Zhiwei
wang, Jinghui
Yao, Man
Liang, Shufang
Lu, Lingeng
CAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment
title CAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment
title_full CAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment
title_fullStr CAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment
title_full_unstemmed CAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment
title_short CAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment
title_sort caxii inhibitors: potential sensitizers for immune checkpoint inhibitors in hcc treatment
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061011/
https://www.ncbi.nlm.nih.gov/pubmed/37006233
http://dx.doi.org/10.3389/fimmu.2023.1052657
work_keys_str_mv AT hanrui caxiiinhibitorspotentialsensitizersforimmunecheckpointinhibitorsinhcctreatment
AT lijiayin caxiiinhibitorspotentialsensitizersforimmunecheckpointinhibitorsinhcctreatment
AT honyjing caxiiinhibitorspotentialsensitizersforimmunecheckpointinhibitorsinhcctreatment
AT xiaozhiwei caxiiinhibitorspotentialsensitizersforimmunecheckpointinhibitorsinhcctreatment
AT wangjinghui caxiiinhibitorspotentialsensitizersforimmunecheckpointinhibitorsinhcctreatment
AT yaoman caxiiinhibitorspotentialsensitizersforimmunecheckpointinhibitorsinhcctreatment
AT liangshufang caxiiinhibitorspotentialsensitizersforimmunecheckpointinhibitorsinhcctreatment
AT lulingeng caxiiinhibitorspotentialsensitizersforimmunecheckpointinhibitorsinhcctreatment